Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. - Jabbour E; Sandhu KS; Shaughnessy P; Logan AC; Abedi M; Shah BD; Bishop MR; Park JH; DeAngelo DJ; Tholouli E; Yallop D; Chaganti S; et al. (Haematologica, 2026)